The purpose of this study is to evaluate the value of AMA in a comparative multicenter regional study as a reference for aggressive lymphoma. The primary endpoint will be RDI. This study consider that the AMA support should allow a significant improvement of the RDI compared to the control group and thus impact the duration without progression. The study covers 350 patients recruited from 10 regional centers.

Inclusion Criteria:

• Patient with a recent diffuse large B cell lymphoma (LBDGC), histologically proven, with treatment not started
• a priori likely to be treated by rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisolone every 21 days (R-CHOP21) for 8 cycles or rituximab, doxorubicin, cyclophosphamide, vindesine, bleomycin, and prednisone (R-ACVBP).
• Index international prognosis (IPI) measurable (IPI-aa), adjusted for age. Any IPI-aa is eligible.
• accepting the study

Exclusion Criteria:

• Patient with another type of lymphoma (including transformed follicular forms)
• Patient having already started his treatment.
• Life expectancy <3 months.
• Carcinologic history
• Serum positive for HIV or hepatitis B virus (HBV).